Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting
Authors:
Sabater J, Ralph L, Batteson R, McCarthy G, Wex J, Vera SRM, Becquart M, Mounedji N, Taieb J, Peeters M and Falcone A.
Publication type:
Conference Proceedings – Poster
Publication Name:
2019 Gastrointestinal Cancers Symposium
Citation:
Sabater J, Ralph L, Batteson R, McCarthy G, Wex J, Vera SRM, Becquart M, Mounedji N, Taieb J, Peeters M and Falcone A. Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting. 2019 Gastrointestinal Cancers Symposium. San Francisco, USA. 17-19 January 2019. Poster 639.
